The role of fecal calprotectin in pediatric disease

Jeong, Su Jin

doi:10.3345/kjp.2019.00059

Cited by 17 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is an important finding as reduction in weight gain can negatively affect the neurodevelopment of preterm infants [ 127 ]. Finally, in the same study, the fermented formula reduced the fecal calprotectin (increased levels of calprotectin are associated with inflammatory gastrointestinal diseases in children) and increased secretory IgA, suggesting immunomodulatory properties [ 126 , 128 , 129 ].…”

Section: Potential Mechanisms Of Actionmentioning

confidence: 93%

Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases

et al. 2020

View full text Add to dashboard Cite

The Sustainable Development goals for 2020 included reducing all causes associated with infant and perinatal mortality in their priorities. The use of compounds with bioactive properties has been proposed as a therapeutic strategy due to their stimulating effect on the host’s immune system. Additionally, biotherapeutic products such as postbiotics, tentatively defined as compounds produced during a fermentation process that support health and well-being, promote intestinal barrier integrity without posing considerable risks to children’s health. Although this is a concept in development, there are increasing studies in the field of nutrition, chemistry, and health that aim to understand how postbiotics can help prevent different types of infections in priority populations such as minors under the age of five. The present review aims to describe the main mechanisms of action of postbiotics. In addition, it presents the available current evidence regarding the effects of postbiotics against pathogens commonly involved in pediatric infections. Postbiotics may constitute a safe alternative capable of modulating the cellular response and stimulating the host’s humoral response.

show abstract

Section: Potential Mechanisms Of Actionmentioning

confidence: 93%

Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We verified a reference range of 33.1–60 μg/g fecal calprotectin in our pediatric population. This differs slightly from the widely-cited cutoff of 50 μg/g fecal calprotectin, however, fecal calprotectin concentrations are reported to be higher in children under 5 years of age [ 11 ]. Our reference range verification included subjects as young as age 2, which may influence our higher cutoff.…”

Section: Discussionmentioning

confidence: 61%

Validation of the newly FDA-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population

Garnett

Pagaduan

Rajapakshe

et al. 2020

Practical Laboratory Medicine

View full text Add to dashboard Cite

Objectives Inflammatory bowel disease (IBD) is an increasingly prevalent disorder marked by chronic intestinal inflammation. Fecal calprotectin has emerged as a useful biomarker for differential diagnostics and monitoring IBD activity. We validated the newly FDA-approved fCal Turbo fecal calprotectin assay in our pediatric hospital. Design and methods The performance of the fCal Turbo assay was assessed on the Vitros 5600 analyzer (Ortho Clinical Diagnostics, USA), including limit of quantitation, linearity, precision, and interference studies. Method comparison was performed with 20 fecal samples with the Buhlmann fCal ELISA, and reference range verification was performed with 33 fecal samples. Results The fCal Turbo assay on the Vitros 5600 was linear between 33.1 and 14,182.5 μg/g, with dilution studies extending the range to 33.1–22,000 μg/g, Reproducibility of the assay met acceptability criteria, with intra-assay CV of 0.3–3.2% and inter-assay CV of 5.2–8.9%. Interference studies identified acceptable thresholds for protein, bilirubin, and lipids. We verified a reference range of 33.1–60 μg/g in our patient population. Deming regression identified acceptable correlation with minor positive bias (2.7%) between the fCal Turbo and fCal ELISA methods. Conclusions The fCal Turbo assay performs well on the Vitros 5600 analyzer in our patient population, with the assay being easy to use in our routine chemistry workflow. We anticipate that the fCal Turbo assay will be useful as a rapid screening method for differential diagnostics and disease monitoring of IBD in our patient population.

show abstract

“…Neutrophils have been found in patients with inflammatory bowel disease (IBD), supporting the hypothesis that the increase in fecal calprotectin is initially a result of increased neutrophil migration into the gut lumen across inflamed mucosa. Apart from anti-infective host-defense roles, it has important proinflammatory properties, and high concentrations can be found during inflammation in the serum and at sites of infection [ 43 , 44 , 45 , 46 , 47 ]. Median faecal calprotectin levels were significantly higher in patients with IBD than in other patients (89% sensitivity and 79% specificity).…”

Section: Markers Found In Von Gierke Disease (Gsdi)mentioning

confidence: 99%

Biomarkers in Glycogen Storage Diseases: An Update

Molares-Vila

Corbalán-Rivas²,

Carnero-Gregorio

et al. 2021

IJMS

View full text Add to dashboard Cite

Glycogen storage diseases (GSDs) are a group of 19 hereditary diseases caused by a lack of one or more enzymes involved in the synthesis or degradation of glycogen and are characterized by deposits or abnormal types of glycogen in tissues. Their frequency is very low and they are considered rare diseases. Except for X-linked type IX, the different types are inherited in an autosomal recessive pattern. In this study we reviewed the literature from 1977 to 2020 concerning GSDs, biomarkers, and metabolic imbalances in the symptoms of some GSDs. Most of the reported studies were performed with very few patients. Classification of emerging biomarkers between different types of diseases (hepatics GSDs, McArdle and PDs and other possible biomarkers) was done for better understanding. Calprotectin for hepatics GSDs and urinary glucose tetrasaccharide for Pompe disease have been approved for clinical use, and most of the markers mentioned in this review only need clinical validation, as a final step for their routine use. Most of the possible biomarkers are implied in hepatocellular adenomas, cardiomyopathies, in malfunction of skeletal muscle, in growth retardation, neutropenia, osteopenia and bowel inflammation. However, a few markers have lost interest due to a great variability of results, which is the case of biotinidase, actin alpha 2, smooth muscle, aorta and fibroblast growth factor receptor 4. This is the first review published on emerging biomarkers with a potential application to GSDs.

show abstract

The role of fecal calprotectin in pediatric disease

Cited by 17 publications

References 38 publications

Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases

Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases

Validation of the newly FDA-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population

Biomarkers in Glycogen Storage Diseases: An Update

Contact Info

Product

Resources

About